Ultradian’s technology is well advanced and initial clinical prototype testing during clinical studies clearly demonstrated our Biologue CGM can accurately track intradermal glucose levels, thus achieving a significant technical milestone. In addition to trade secrets and know-how, part of Ultradian’s intellectual property portfolio is focused on the following technology:
There are US and European patents pending for improved accuracy and diabetes diagnostic applications of in vivo sensor measurements. This technology is covered under the broader category of method, system and device patents for a “Biofouling Self-Compensating Biosensor” (US Pat App. 20070299617). This technology reduces the necessity for frequent fingerstick re-calibration of in vivo sensors thereby greatly improving accuracy. Ultradian’s superior accuracy will have a significant impact on the adoption rate of continuous glucose monitoring as a replacement for fingerstick testing for the management of diabetes.